REVIEW
|
doi:10.20944/preprints202402.1049.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
malignant pleural mesothelioma; immune checkpoint inhibitor; orphan drug; good clinical practice; Pharmaceuticals and Medical Devices Agency
Online: 20 February 2024 (04:03:22 CET)